ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0442

Identification of Plexin D1 on Circulating Extracellular Vesicles as a Potential Biomarker of Polymyositis and Dermatomyositis

Kenichi Uto1, Koji Ueda2, Takaichi Okano1, Kengo Akashi1, Soshi Takahashi3, Yuji Nakamachi4, Takamitsu Imanishi1, Seiji Kawano1, Yoshihiko Yano5 and Jun Saegusa6, 1Kobe University Hospital, Kobe, Japan, 2Japanese Foundation for Cancer Research, Tokyo, Japan, 3Shinko Hospital, Kobe, Japan, 4Kobe University School of Medicine, Kobe, Japan, 5Department of Clinical Laboratory, Kobe University Hospital, Kobe, Japan, 6Rheumatology and Clinical Immunology, Kobe University Hospital, Kobe, Japan

Meeting: ACR Convergence 2021

Keywords: Biomarkers, informatics, Myositis, proteomics

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Abstracts: Muscle Biology, Myositis & Myopathies (0441–0444)

Session Type: Abstract Session

Session Time: 9:15AM-9:30AM

Background/Purpose: Extracellular vesicles (EVs), including exosomes and microvesicles, are small membrane vesicles released by almost all cell types and are found circulating in blood and other body fluids. Circulating EVs are promising as a novel type of systemic biomarker for various different diseases because their cargoes (miRNAs, mRNAs, and proteins) reflect their cellular origin and function. Increasing evidence suggests that surface proteins (e.g. membrane proteins) on EVs, especially exosomes, are altered in pathological conditions and useful as non-invasive biomarkers for cancer diagnosis and prognosis. However, they have rarely been employed as serum biomarkers for autoimmune diseases. The aim of this study is to identify disease-specific surface proteins on EVs as novel serum biomarkers of polymyositis and dermatomyositis (PM/DM).

Methods: Serum EVs were purified by size exclusion chromatography using sera of 10 PM/DM, 23 patients with other autoimmune diseases and 10 healthy controls (HC). Comprehensive proteomic analysis of serum EVs was performed by liquid chromatography-tandem mass spectrometry (LC/MS). We identified membrane proteins preferentially present in serum EVs of PM/DM patients by bioinformatics and biostatistical analyses. We developed sandwich ELISA for directly detecting serum EVs expressing disease-specific membrane proteins and measured their expression levels using sera of 54 PM/DM, 24 rheumatoid arthritis (RA), 20 systemic lupus erythematosus (SLE), 13 systemic sclerosis patients, and 36 HC.

Results: LC/MS analysis identified 1,220 proteins in serum EVs. From the volcano plots combining different bioinformatics analyses (DAVID gene ontology and UniProtKB/Swiss-prot), we identified 5 membrane proteins as significantly up-regulated in serum EVs of PM/DM patients. Of these, Plexin D1 was enriched in those from PM/DM patients relative to HC (p=0.0237) or patients without PM/DM (p=0.0593). Using our sandwich ELISA, we found that levels of Plexin D1-positive EVs (Plexin D1+ EVs) in serum were significantly greater in PM/DM patients than in HC (p=0.0016), RA (p< 0.0001) or SLE patients (p< 0.0001). Serum levels of Plexin D1+ EVs were greater in those PM/DM patients with muscle pain or weakness (p=0.0428). Serum levels of Plexin D1+ EVs were correlated with levels of aldolase (rs=0.481, p=0.027), total blood cells (rs=0.381, p=0.046), neutrophils (rs=0.450, p=0.019), and platelets (rs=0.408, p=0.031) in PM/DM patients. Finally, serum levels of Plexin D1+ EVs decreased significantly in patients with PM/DM in clinical remission after treatment (p< 0.0001).

Conclusion: We have identified levels of circulating Plexin D1+ EVs as a novel serum biomarker for PM/DM.

Serum levels of Plexin D1-positive EVs are higher in PM/DM patients with associated muscle pain or weakness

Serum levels of Plexin D1-positive EVs are decreased in PM/DM patients after treatment.
Change of serum levels of CD9+ Plexin D1+ EVs in PM/DM patients after treatment in 21 PM/DM patients who achieved clinical remission (left) and 3 PM/DM patients who did not (right).


Disclosures: K. Uto, None; K. Ueda, None; T. Okano, None; K. Akashi, None; S. Takahashi, None; Y. Nakamachi, None; T. Imanishi, None; S. Kawano, None; Y. Yano, None; J. Saegusa, None.

To cite this abstract in AMA style:

Uto K, Ueda K, Okano T, Akashi K, Takahashi S, Nakamachi Y, Imanishi T, Kawano S, Yano Y, Saegusa J. Identification of Plexin D1 on Circulating Extracellular Vesicles as a Potential Biomarker of Polymyositis and Dermatomyositis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/identification-of-plexin-d1-on-circulating-extracellular-vesicles-as-a-potential-biomarker-of-polymyositis-and-dermatomyositis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-plexin-d1-on-circulating-extracellular-vesicles-as-a-potential-biomarker-of-polymyositis-and-dermatomyositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology